IMPORTATION AND INNOVATION

References

• Abbott , T. A. and Vernon , J. A. 2005 . The Cost of US Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Reductions . February NBER Working Paper No. 11114
   Google Scholar
• Caves , R. , Whinston , M. and Hurwitz , M. 1991 . Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry . Brookings Papers on Economic Activity: Microeconomics , : 1 – 48 .
   Web of Science ®Google Scholar
• Danzon , P. , Wang , Y. R. and Wang , L. 2005 . The Impact of Price Regulation on the Launch Delay of New Drugs–Evidence from 25 Major Markets in the 1990s . Health Economics , 14 : 269 – 292 .
   PubMed Web of Science ®Google Scholar
• Department of Health Human Services . 2000 . Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices . April
   Google Scholar
• Folland , S. , Goodman , A. and Stano , M. 2001 . The Economics of Health and Health Care, , 3rd , Upper Saddle River, NJ : Prentice Hall .
   Google Scholar
• Giaccotto , C. , Santerre , R. E. and Vernon , J. A. 2005 . Pharmaceutical Pricing and R&D Growth Rates . Journal of Law and Economics , 48 : 195 – 214 .
   Web of Science ®Google Scholar
• Goldman , D. P. , Joyce , G. F. and Malkin , J. D. 2002 . The Costs of a Medicare Prescription Drug Benefit: A Comparison of Alternatives, RAND Corporation, MR-1529.0-NIA . Available online at: http://www.rand.org/publications/MR/MR1529.0/economic.html
   Google Scholar
• Grabowski , H. and Vernon , J. 1992 . Brand Loyalty, Entry and Price Competition in Pharmaceuticals After the 1984 Drug Act . Journal of Law and Economics , 35 : 331 – 350 .
   Web of Science ®Google Scholar
• Grabowski , H. and Vernon , J. 1996 . Longer Patents for Increased Generic Competition in the US . Pharmaco Economics , 10 ( Supp. 2 ) : 110 – 123 .
   PubMed Web of Science ®Google Scholar
• Hughes , J. W. , Moore , M. J. and Edward Snyder , A. 2002 . ‘Napsterizing’ Pharmaceuticals: Access, Innovation, and Consumer Welfare . October NBER Working Paper 9229
   Google Scholar
• Kyle , M. K. March 9 2005 . “ Pharmaceutical Price Controls and Entry Strategies ” . March 9 , Duke University . unpublished paper
   Google Scholar
• Lichtenberg , F. R. 2005a . ‘Availability of New Drugs and Americans’ Ability to work . Journal of Occupational and Environmental Medicine , 47 ( 4 ) : 373 – 380 .
   PubMed Web of Science ®Google Scholar
• Lichtenberg , F. R. 2005b . The Impact of New Drug Launches on Longevity: Evidence from Longitudinal Disease-level Data from 52 Countries. 1982–2001 . International Journal of Health Care Finance and Economics , 5 : 47 – 73 .
   PubMedGoogle Scholar
• Lichtenberg , F. R. 2005c . “ Pharmaceutical Knowledge-Capital Accumulation and Longevity ” . In Measuring Capital in the New Economy , Edited by: Corrado , C. , Haltiwanger , J. and Sichel , D. 237 – 269 . Chicago, IL : University of Chicago Press .
   Google Scholar
• Lillard , L. A , Rogowski , J. and Kington , R. 1999 . Insurance Coverage for Prescription Drugs: Effects on Use and Expenditures in the Medicare Population . Medical Care , 37 ( 9 ) : 926 – 936 .
   PubMed Web of Science ®Google Scholar
• Merino-Castelló , A. 2003 . Demand for Pharmaceutical Drugs: a Choice Modelling Experiment . June Available at: http://www.econ.upf.es/docs/papers/downloads/704.pdf
   Google Scholar
• Scherer , F. M. 2001 . The Link Between Gross Profitability and Pharmaceutical R&D Spending . Health Affairs , 20 ( 5 ) : 216 – 20 .
   Web of Science ®Google Scholar
• Schumpeter , J. A. 1947 . Capitalism, Socialism, and Democracy, , 2nd , New York, London : Harper & brothers .
   Google Scholar